Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.
22.04.2025 12:24:14

Danaher Q1 Results Down, Beats Market; Sees Higher Core Revenues In Q2, Backs FY25 View; Stock Up

(RTTNews) - Danaher Corp. (DHR), while reporting weak first-quarter results, but above market estimates, on Tuesday issued outlook for second-quarter revenue and fiscal 2025 earnings. Further, the company maintained annual core revenue growth view.

In pre-market activity on the NYSE, the life sciences and diagnostics company's shares were gaining around 2.8 percent to trade at $190.06.

For the second quarter 2025, the company anticipates that adjusted core revenue will grow low-single digits year-over-year.

For full year 2025, the company expects adjusted net earnings per share in the range of $7.60 to $7.75.

The Wall Street analysts on average expect the company to report earnings of $7.67 per share. Analysts' estimates typically exclude special items.

Further, the firm continues to expect adjusted core revenue for the year to grow approximately 3 percent year-over-year.

In its first quarter, net earnings fell to $954 million from last year's $1.09 billion. Earnings per share declined to $1.32 from $1.45 a year ago.

Adjusted net earnings per share were $1.88, compared to $1.92 last year. The analysts expected the company to report earnings of $1.64 per share.

Revenues decreased 1 percent to $5.74 billion from $5.80 billion in the prior year. Adjusted core revenue was flat year-over-year. Analysts expected revenues of $5.59 billion for the quarter.

Rainer Blair, President and Chief Executive Officer, stated, "Revenue, earnings, and cash flow exceeded our expectations in the first quarter-highlighted by continued momentum in bioprocessing and better-than-expected respiratory demand in our molecular diagnostics business."

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

Analysen zu Danaher Corp.

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

3 Knaller-Aktien 📈im BX Musterportfolio: Trane Techn., Cintas & Deutsche Boerse mit François Bloch

Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ Trane Technologies
✅ Cintas
✅ Deutsche Boerse

Pünktlich zum Börsenstart diskutieren Investment-Stratege François Bloch und Börsen-Experte David Kunz oder Olivia Hähnel über ausgewählte Top-Aktienwerte aus dem BX Musterportfolio.

👉🏽 https://bxplus.ch/bx-musterportfolio/

3 Knaller-Aktien 📈im BX Musterportfolio: Trane Technologies, Cintas & Deutsche Boerse mit François Bloch

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’668.58 18.60 BNRSDU
Short 12’901.17 13.50 SS4MTU
Short 13’370.90 8.78 B02SIU
SMI-Kurs: 12’269.95 22.05.2025 17:31:45
Long 11’716.05 19.68 BX7SBU
Long 11’419.73 13.19 BXGS2U
Long 10’972.12 8.85 BAOSEU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

Coinbase am 22.05.2025

Chart

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}